BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 23041121)

  • 1. The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB.
    Lilja AE; Mason PW
    Vaccine; 2012 Nov; 30(49):6980-90. PubMed ID: 23041121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Additive Protection against Congenital Cytomegalovirus Conferred by Combined Glycoprotein B/pp65 Vaccination Using a Lymphocytic Choriomeningitis Virus Vector.
    Schleiss MR; Berka U; Watson E; Aistleithner M; Kiefmann B; Mangeat B; Swanson EC; Gillis PA; Hernandez-Alvarado N; Fernández-Alarcón C; Zabeli JC; Pinschewer DD; Lilja AE; Schwendinger M; Guirakhoo F; Monath TP; Orlinger KK
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27795301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Reponses against Human Cytomegalovirus in Mice.
    Chiuppesi F; Nguyen J; Park S; Contreras H; Kha M; Meng Z; Kaltcheva T; Iniguez A; Martinez J; La Rosa C; Wussow F; Diamond DJ
    J Virol; 2018 Oct; 92(19):. PubMed ID: 30045984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.
    Reap EA; Dryga SA; Morris J; Rivers B; Norberg PK; Olmsted RA; Chulay JD
    Clin Vaccine Immunol; 2007 Jun; 14(6):748-55. PubMed ID: 17442845
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vectored co-delivery of human cytomegalovirus gH and gL proteins elicits potent complement-independent neutralizing antibodies.
    Loomis RJ; Lilja AE; Monroe J; Balabanis KA; Brito LA; Palladino G; Franti M; Mandl CW; Barnett SW; Mason PW
    Vaccine; 2013 Jan; 31(6):919-26. PubMed ID: 23246547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity evaluation of DNA vaccines that target guinea pig cytomegalovirus proteins glycoprotein B and UL83.
    Schleiss MR; Bourne N; Jensen NJ; Bravo F; Bernstein DI
    Viral Immunol; 2000; 13(2):155-67. PubMed ID: 10892996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults.
    Bernstein DI; Schleiss MR; Berencsi K; Gonczol E; Dickey M; Khoury P; Cadoz M; Meric C; Zahradnik J; Duliege AM; Plotkin S
    J Infect Dis; 2002 Mar; 185(5):686-90. PubMed ID: 11865427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functionally inactivated dominant viral antigens of human cytomegalovirus delivered in replication incompetent adenovirus type 6 vectors as vaccine candidates.
    Tang A; Freed DC; Li F; Meschino S; Prokop M; Bett A; Casimiro D; Wang D; Fu TM
    Hum Vaccin Immunother; 2017 Dec; 13(12):2763-2771. PubMed ID: 28494195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replication-defective lymphocytic choriomeningitis virus vectors expressing guinea pig cytomegalovirus gB and pp65 homologs are protective against congenital guinea pig cytomegalovirus infection.
    Cardin RD; Bravo FJ; Pullum DA; Orlinger K; Watson EM; Aspoeck A; Fuhrmann G; Guirakhoo F; Monath T; Bernstein DI
    Vaccine; 2016 Apr; 34(17):1993-9. PubMed ID: 26973071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.
    Bernstein DI; Munoz FM; Callahan ST; Rupp R; Wootton SH; Edwards KM; Turley CB; Stanberry LR; Patel SM; Mcneal MM; Pichon S; Amegashie C; Bellamy AR
    Vaccine; 2016 Jan; 34(3):313-9. PubMed ID: 26657184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.
    Wang Z; La Rosa C; Lacey SF; Maas R; Mekhoubad S; Britt WJ; Diamond DJ
    J Clin Virol; 2006 Mar; 35(3):324-31. PubMed ID: 16388983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.
    Nelson CS; Jenks JA; Pardi N; Goodwin M; Roark H; Edwards W; McLellan JS; Pollara J; Weissman D; Permar SR
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32051265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection against pup mortality.
    Swanson EC; Gillis P; Hernandez-Alvarado N; Fernández-Alarcón C; Schmit M; Zabeli JC; Wussow F; Diamond DJ; Schleiss MR
    Vaccine; 2015 Jul; 33(32):4013-8. PubMed ID: 26079615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refinement in the production and purification of recombinant HCMV IE1-pp65 protein for the generation of epitope-specific T cell immunity.
    Nguyen TH; Mifsud NA; Stewart LA; Rose MJ; Etto TL; Williamson NA; Purcell AW; Kotsimbos T; Schwarer AP
    Protein Expr Purif; 2008 Sep; 61(1):22-30. PubMed ID: 18539483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects.
    Berencsi K; Gyulai Z; Gönczöl E; Pincus S; Cox WI; Michelson S; Kari L; Meric C; Cadoz M; Zahradnik J; Starr S; Plotkin S
    J Infect Dis; 2001 Apr; 183(8):1171-9. PubMed ID: 11262198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.
    Abel K; Strelow L; Yue Y; Eberhardt MK; Schmidt KA; Barry PA
    Vaccine; 2008 Nov; 26(47):6013-25. PubMed ID: 18760319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrahost Dynamics of Human Cytomegalovirus Variants Acquired by Seronegative Glycoprotein B Vaccinees.
    Nelson CS; Vera Cruz D; Su M; Xie G; Vandergrift N; Pass RF; Forman M; Diener-West M; Koelle K; Arav-Boger R; Permar SR
    J Virol; 2019 Mar; 93(5):. PubMed ID: 30518646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Construction and transfection of eucaryotic expression recombinant vector containing truncated region of UL83 gene of human cytomegalovirus and it's sheltered effect as DNA vaccine].
    Gao RB; Li YQ; Wang ML
    Wei Sheng Wu Xue Bao; 2006 Jun; 46(3):451-5. PubMed ID: 16933619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimized recombinant dense bodies of human cytomegalovirus efficiently prime virus specific lymphocytes and neutralizing antibodies without the addition of adjuvant.
    Becke S; Aue S; Thomas D; Schader S; Podlech J; Bopp T; Sedmak T; Wolfrum U; Plachter B; Reyda S
    Vaccine; 2010 Aug; 28(38):6191-8. PubMed ID: 20655401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines for cytomegalovirus.
    Bernstein DI
    Infect Disord Drug Targets; 2011 Oct; 11(5):514-25. PubMed ID: 22309618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.